Moderna's COVID-19 mRNA vaccine enters Phase 2 with human testing

On Friday, Moderna announced that its mRNA vaccine targeting the novel coronavirus behind COVID-19 has been given to the initial round of humans participating in its Phase 2 trial. The announcement comes only two weeks after Moderna detailed the results from its Phase 1 testing, which involved dosing people ages 18 to 55. If all goes as planned, the Phase …